BENCHSCI
BenchSci uses AI to empower scientists to run more successful experiments to accelerate drug discovery. The company empowers scientists with advanced biomedical artificial intelligence to run more successful experiments. Backed by F-Prime, Gradient Ventures (Google’s AI fund), and Inovia Capital, BenchSci's proprietary technology accelerates science pharmaceutical companies and over 4,300 research centers worldwide.
BENCHSCI
Industry:
Artificial Intelligence (AI) Biotechnology Life Science Machine Learning Pharmaceutical
Founded:
2015-01-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.benchsci.com
Total Employee:
251+
Status:
Active
Contact:
+1 437-370-8077
Email Addresses:
[email protected]
Total Funding:
164.14 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving SSL By Default Google Tag Manager Apple Mobile Web Clips Icon Google Font API HSTS Google Analytics Google Maps
Similar Organizations
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Elucidata
Elucidata delivers ML-ready biomedical molecular data that is curated to accelerate drug discovery.
Iroko Pharmaceuticals
Iroko Pharmaceuticals is a global specialty pharmaceutical company dedicated to advancing the science of analgesia.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
Current Advisors List
Current Employees Featured
Founder
Investors List
Inovia Capital
Inovia Capital investment in Series D - BenchSci
Golden Ventures
Golden Ventures investment in Series D - BenchSci
Generation Investment Management
Generation Investment Management investment in Series D - BenchSci
TCV
TCV investment in Series D - BenchSci
F-Prime Capital
F-Prime Capital investment in Series D - BenchSci
BDC Venture Capital
BDC Venture Capital investment in Series D - BenchSci
TCV
TCV investment in Series C - BenchSci
Inovia Capital
Inovia Capital investment in Series C - BenchSci
F-Prime Capital
F-Prime Capital investment in Series B - BenchSci
Inovia Capital
Inovia Capital investment in Series B - BenchSci
Key Employee Changes
Official Site Inspections
http://www.benchsci.com Semrush global rank: 1.59 M Semrush visits lastest month: 15.54 K
- Host name: 199.60.103.184
- IP address: 199.60.103.184
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto
More informations about "BenchSci"
About Us - BenchSci
What scientists discovered was that BenchSci and our visual ML had built the first objective map of the underlying biology of disease. So, working in secret with top partners and global pharma R&D leaders, we launched Project Butterfly—an …See details»
BenchSci - LinkedIn
BenchSci’s vision is to exponentially increase the speed and quality of life-saving research by empowering scientists with the world’s most advanced biomedical artificial intelligence.See details»
BenchSci - Crunchbase Company Profile & Funding
BenchSci uses AI to empower scientists to run more successful experiments to accelerate drug discovery. The company empowers scientists with advanced biomedical artificial intelligence to run more successful experiments. Backed …See details»
BenchSci Careers and Employment | Indeed.com
BenchSci’s vision is to bring novel medicine to patients 50% faster by 2025. We’re achieving it by empowering scientists with the world’s most advanced biomedical artificial intelligence to run …See details»
BenchSci Named One of Canada’s Most Admired Corporate …
BenchSci is a world leader in AI solutions for drug discovery on a mission to exponentially increase the speed and quality of life-saving R&D to help bring new medicines to patients …See details»
The BenchSci Story
Sep 15, 2016 Tom Leung is the Chief Science Officer and Co-Founder of BenchSci. With an MSc in virology and a Ph.D. in epigenetics from the University of Toronto, Tom’s research focused on the molecular mechanism of …See details»
Introducing ASCEND™ by BenchSci, our innovative new …
Jan 31, 2023 As a result, a powerful and proprietary view of an organization's unique biological insights, from across its research history, is instantly at its scientists’ fingertips. ... Liran Belenzon, co-founder and CEO of BenchSci, …See details»
How comprehensive is BenchSci's database? | Knowledge Center
Oct 15, 2024 BenchSci has the world’s most powerful and comprehensive biomedical experiment-focused dataset and ontology, built using proprietary machine learning models that …See details»
The BenchSci Culture Story: Achieving Success Beyond …
Feb 9, 2022 At BenchSci, our mission is to exponentially increase the speed and quality of life-saving research. We've been fortunate to experience a lot of growth over the past few years, doubling in size from 100 to 200 team members in …See details»
BenchSci Announces Launch of ASCEND
Toronto, CANADA, January 31, 2023 — BenchSci, a world leader in AI solutions for drug discovery, today announced the launch of its latest technology, ASCEND by BenchSci, helping …See details»
General Information about BenchSci Data | Knowledge Center
It's big. And it's only getting bigger! BenchSci has the world’s most powerful and comprehensive biomedical experiment-focused dataset and ontology, built using proprietary machine learning …See details»
How Comprehensive is BenchSci’s Data and Where Do We Get It?
Sep 8, 2021 BenchSci is a powerful technology that scientists can leverage to quickly find the data they’re looking for, helping them accelerate their research and get novel medicine to …See details»
News - BenchSci
BenchSci Named One of Canada’s Most Admired Corporate Cultures by Waterstone Human Capital Read More. Nov 6, 2024 BenchSci Announced as One of Deloitte’s Technology Fast …See details»
BenchSci for Academics: Find your next antibody
Leverage the combined data of 20 million peer-reviewed publications, preprints, 14 million commercial products, and third-party data to choose the most appropriate antibody.See details»
BenchSci Raises $63 Million Series C to Solve Pharma's
Jan 24, 2022 BenchSci’s vision is to bring novel medicine to patients 50% faster by 2025. We’re achieving it by empowering scientists with the world’s most advanced biomedical artificial …See details»
BenchSci Expands Scientists’ Access to World-Class Research …
Toronto, CANADA, September 9, 2024 —BenchSci, a world leader in AI solutions for preclinical research and drug discovery, today announced a new partnership with The Company of …See details»
BenchSci Ranked 26 on the 2021 List of 50 Best Workplaces in …
In April 2021, BenchSci was named #26 on the List of 50 Best Workplaces in Canada. Read more about some of the things we're doing that helped us get there. BenchSci Ranked 26 on the …See details»
Benchsci
How can we help you? Open in Full Website Scroll to Top Scroll to TopSee details»
How BenchSci Got Started
Apr 19, 2022 This July marks five years since BenchSci launched its first product and we hire more talent to join us in hypergrowth (see our open roles), I thought now would be a good time …See details»